Global Medical Cyclotron Market Report 2025: Size Projected USD 493.8 Billion, CAGR of 6.93% by 2033.

Market Overview

The global Medical Cyclotron Market was valued at USD 265.4 Million in 2025 and is projected to reach USD 493.8 Million by 2034, exhibiting a CAGR of 6.93% during 2026-2034. The growth is driven by rising cancer prevalence, advancements in radiopharmaceuticals, growing demand for PET scans, technological innovations, expanding healthcare infrastructure, and supportive government initiatives promoting nuclear medicine and diagnostic imaging.

Study Assumption Years

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

Medical Cyclotron Market Key Takeaways

• The global medical cyclotron market size was valued at USD 265.4 Million in 2025 and is expected to reach USD 493.8 Million by 2034.
• It is projected to grow at a CAGR of 6.93% during 2026-2034.
• Asia Pacific dominated the market in 2025 due to robust healthcare infrastructure expansion and rising cancer prevalence.
• Increasing demand for advanced diagnostic imaging, especially PET scans that rely on radioisotopes produced by cyclotrons, fuels market growth.
• Technological advancements in radiopharmaceuticals have expanded applications beyond oncology, including cardiology and neurology.
• Expanding healthcare infrastructure and government funding in emerging economies support cyclotron adoption.

Sample Request Link: https://www.imarcgroup.com/medical-cyclotron-market/requestsample

Market Growth Factors

The medical cyclotron market is primarily driven by the rising prevalence of cancer and other chronic diseases globally. In 2022, cancer caused 9.7 million deaths with 53.5 million people living with a cancer diagnosis. Medical cyclotrons produce radioisotopes essential for PET scans that facilitate early-stage cancer detection. Additionally, diseases such as cardiovascular disorders and neurological conditions have increased demand for precise diagnostic imaging, strengthening the need for reliable radioisotopes.

Advancements in radiopharmaceuticals further propel market growth. In 2024, the global radiopharmaceuticals market reached USD 5.8 Billion and is forecasted to grow to USD 8.9 Billion by 2033 at a CAGR of 4.9%. Innovations include the development of targeted radiopharmaceuticals improving diagnostic accuracy and treatment efficacy, as well as integration of AI and machine learning to develop new compounds, expanding the production needs for novel radioisotopes.

Expanding healthcare infrastructure and investments in diagnostic imaging, especially in emerging economies like India, support market expansion. For example, India's healthcare facilities include 1,69,615 Sub-Centres and 31,882 Primary Health Centres as of March 2023. Increasing establishment of PET and PET-CT centers, and government initiatives enhancing access to advanced diagnostic equipment and radiopharmaceuticals, contribute positively.

Supportive public-private partnerships and funding for cancer diagnostics further strengthen the adoption of medical cyclotrons.

Market Segmentation

Analysis by Type:

• Ring Cyclotron: The largest segment in 2025, noted for high-energy radioisotope production, continuous particle acceleration, and versatility across oncology, cardiology, and neurology.
• Azimuthally Varying Field (AVF) Cyclotron: Present as a distinct category though detailed specifics were not provided beyond being a categorized type.

Analysis by Product Type:

• Cyclotron 16-18 MeV: Led the market in 2025 due to optimal balance of production capacity and operational efficiency. Produces essential isotopes like Fluorine-18 for PET imaging, suitable for hospitals and commercial radiopharmacies, offering cost-effectiveness and versatility.
• Cyclotron 10-12 MeV, Cyclotron 19-24 MeV, Cyclotron 24 MeV and Above: These categories are listed but detailed data on market positioning or attributes were not provided.

Analysis by End User:

• Hospitals: The largest end user in 2025, utilizing medical cyclotrons for in-house production of radioisotopes used in PET and SPECT imaging critical for diagnosing cancer, cardiovascular and neurological diseases.
• Diagnostic Centers, Research and Academic Institutes, Others: These segments are identified but detailed insights were not expanded upon.

Regional Insights

Asia Pacific was the dominant region in 2025 due to robust healthcare infrastructure expansion, especially in China, Japan, and India. Government investments and policies support medical cyclotron adoption, while increasing cancer and chronic disease prevalence further increases market demand. The region benefits from active research and development, and presence of major cyclotron manufacturers, consolidating its market leadership.

Recent Developments & News

In February 2025, the State Government of Nagpur planned to establish a cyclotron center for cancer detection and nuclear research, also serving industries like semiconductors and metallurgy. Framatome partnered with IBA to industrially manufacture the alpha-emitting radioisotope Astatine-211 in the US and Europe, aiming to develop a dependable network of specialized cyclotrons. In late 2024, NISER Bhubaneswar announced plans to start building a medical cyclotron facility to manufacture radioisotopes for vital imaging tests. The African Medical Centre of Excellence in Abuja also announced plans to establish a cyclotron facility focused on complex diseases diagnosis and treatment.

Contact Out Analysts for Brochure Requests, Customization, and Inquiries Before Purchase: https://www.imarcgroup.com/request?type=report&id=4573&flag=C

Key Players

• Advanced Cyclotron Systems Inc.
• Alcen
• Best Medical International Inc.
• General Electric Company
• IBA RadioPharma Solutions
• Ionetix Corporation
• Isosolution Inc.
• Siemens AG
• Sumitomo Heavy Industries Ltd.
• Varian Medical Systems Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉 Get Custom Market Research for Your Business:- https://www.imarcgroup.com/request?type=report&id=4573&flag=E

Contact Us

IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.